Wolfe Research upgraded Guardant Health (GH) to Outperform from Peer Perform with a $75 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $80 from $70 at UBS
- Guardant Health’s Strategic Advancements and Growth Potential Earns Buy Rating
- Guardant Health Hosts Investor Day in NYC
- Guardant Health, Quest Diagnostics announce blood-based screening test pact
- Guardant Health: Buy Rating Backed by Growth Potential and Innovation in Cancer Screening